California Dog Park Closes After Mystery Illness Hits Multiple Pets
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A popular dog park in Bay Area city Santa Clara in California, has been closed indefinitely after multiple dogs became sick following visits there in recent weeks, including at least one that died last month.
City officials announced on August 4 that Nuevo Dog Park will be closed until further notice as a "precautionary measure" while tests are carried out.
Newsweek has contacted the City of Santa Clara for comment.
Why It Matters
Multiple dogs have been affected in recent weeks, and the park's closure highlights the urgency of the situation. City officials said in an announcement that shutting down the park was a necessary step to protect other animals while tests are conducted.
What To Know
According to a news release from the City of Santa Clara, several dogs became ill after visiting Nuevo Dog Park, and one "sadly passed away" during the week of July 28 after a visit to the park.
Another dog, Benji—a 4-year-old mini Australian shepherd—also died on June 15 after having two seizures following a visit to the park, NBC Bay Area reported. Several dogs have showed symptoms such as vomiting, diarrhea and seizures.
City staff stressed that pesticides are not used in any dog parks. "All are regularly cleaned with pet- and eco-friendly products. We are taking these concerns seriously," the news release said.
Resident Juliana Martinez told NBC Bay Area that her dog, Ozzy, began trembling violently after a visit, prompting her to post warning signs outside the park.
"It was really traumatizing for me and my boyfriend; we just didn't know what was going on," Martinez said "We were scared obviously. Once we got to the vet, they thought he had epilepsy."
A Samoyed named Boba was left "fighting for his life" after suffering seizures that "led to a heatstroke causing multiple damages internally," owner Tony Wang told local news outlet KQED.
Dog owner Marianne Saint George was surprised to hear of the closure, telling ABC7 News on August 6: "I literally had no idea there was a health concern here. I thought it was closed because the gate had been vandalized."
Her two dogs, Esmerelda and Rosemary, had suffered bouts of diarrhea lasting several days, prompting her to seek advice from a veterinarian, she said.
Chanu Malla told the news outlet his dog Bella also suffered violent seizures after visiting the park and he "wasn't sure if she was going to make it during the 10-minute drive to the vet."
"It was really scary. I've never had major health issues like that with her before," Malla said.
What People Are Saying
The City of Santa Clara said in a news release on August 4: "We extend our heartfelt sympathies to the pet's family—we understand that pets are cherished members of our community.
"The health and safety of Santa Clara residents, including their four-legged companions, is a top priority."
What Happens Next
Environmental testing at Nuevo Dog Park is underway, and the city has not given a timeline for reopening.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
22 minutes ago
- Newsweek
Millions Told To Monitor Unusual Fatigue, Palpitations
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Millions of Americans have been urged to watch out for unusual fatigue and palpitations amid concerns over high air pollution levels. The National Weather Service (NWS) issued a series of air quality alerts on Tuesday for large swathes of Minnesota, Wisconsin, New York, Connecticut, New Hampshire, Rhode Island, Massachusetts, Colorado, Texas and California. The warnings mean ground-level ozone and particulate concentrations are forecast to reach dangerous levels. In some areas, the pollution comes from drifting wildfire smoke. Why It Matters The NWS warned that the general public as well as sensitive groups — children, seniors, and individuals with preexisting respiratory or heart conditions—might experience health effects linked to poor air quality in the affected regions. "People with heart disease: symptoms such as palpitations, shortness of breath, or unusual fatigue may indicate a serious problem. If you have any of these, contact your health care provider," it said. "People with asthma: follow your asthma action plan and keep quick relief medicine handy." It added: "Sensitive groups, such as people with lung disease, heart disease, and children and older adults, should avoid prolonged or heavy exertion." The Statue of Liberty is seen through haze from Canadian wildfires earlier in August. The Statue of Liberty is seen through haze from Canadian wildfires earlier in August. Yuki Iwamura/AP What To Know In Connecticut and Rhode Island, Air Quality Action Days have been issued until 11 p.m. on Tuesday, covering urban areas such as New Haven, Hartford, Providence and Newport. The alerts mean that ground level ozone levels may approach or exceed unhealthy standards. Air quality alerts have been issued in New York and Massachusetts until 11 p.m., covering areas including the Bronx, Queens, Boston and Plymouth. In New Hampshire, an air quality alert has been issued until 10 p.m. In Minnesota, an air quality alert for fine particle pollution has been issued until 9 a.m., and in Wisconsin an air quality advisory has been issued for most northern counties until 3 p.m. Meanwhile in Colorado, an air quality health advisory for wildfire smoke has been issued for a number of western counties until 9 a.m. following the Stoner Mesa fire. In California, an air quality alert has been issued due to harmful levels of particle pollution from windblown dust in the Coachella Valley. And in Texas, an Ozone Action Day has been issued for the Dallas-Fort Worth area. What People Are Saying The Colorado Department of Public Health and Environment said: "If smoke is thick or becomes thick in your neighborhood you may want to remain indoors. This is especially true for those with heart disease, respiratory illnesses, the very young, and older adults. Consider limiting outdoor activity when moderate to heavy smoke is present. Consider relocating temporarily if smoke is present indoors and is making you ill." California's South Coast Air Quality Management District said: "Particle pollution can get deep into the lungs and cause serious health problems such as asthma attacks, heart and lung disease symptoms, and increased risk of lung infections. Everyone can be affected, but sensitive groups such as people with lung or heart disease, older adults, people who are pregnant, children, and those who spend a lot of time outdoors are at greater risk." Jonathan Grigg, a professor of pediatric respiratory and environmental medicine at Queen Mary University of London, previously told Newsweek that there are "very clear links" between inhaling particles and earlier death from both respiratory and cardiovascular diseases. He added: "There are vulnerable groups and classically they are children because they've got an extra issue to do with their lungs developing, whereas our lungs are not developing as adults." What Happens Next The majority of the air quality alerts are currently set to remain in force until late Tuesday. Regular updates regarding air pollution levels are issued on the NWS website and on the Environmental Protection Agency's AirNow interactive map.
Newsweek
14 hours ago
- Newsweek
Chocolate Recall Sparks Nationwide Warning to Customers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Neuhaus Chocolates NV is recalling their Belgian Chocolate Moments Smurfs 'Popping Milk Chocolates with Cookies because the product contains wheat which was not declared on the packaging. Newsweek reached out to the company via email Monday for comment. Why It Matters Numerous recalls have been initiated this year due to the potential for damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the U.S. Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. People with a wheat allergy could experience a "serious or life-threatening allergic reaction if they consume these products," the FDA warns. What To Know Neuhaus Chocolate can be seen related to a recall in August 2025. (Photo from the U.S. Food and Drug Administration) Neuhaus Chocolate can be seen related to a recall in August 2025. (Photo from the U.S. Food and Drug Administration) In the alert, the FDA says the recalled chocolates were distributed from July 21, 2025, until August 4, 2025, by Neuhaus stores in Virginia, New York, Pennsylvania, Maryland, Washington, D.C. and via their online store. The impacted batch numbers are 80108690 and 80108763 with a best use before date of January 13, 2026, the FDA alert says. There have been no reports of illnesses related to this recall and 150 units of the impacted products were sold, the FDA says. What People Are Saying The FDA in their alert in part: "The action was initiated after it was discovered during an internal check that product containing wheat was distributed in packaging that did not reveal the presence of wheat. Subsequent investigation indicates the problem was caused by an exceptional combination of circumstances in which the ERP (Enterprise Resource Planning) did not include the allergen on the packaging." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall; the FDA shares that release on our website as a public service. "The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall. "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts. What Happens Next Customers who have purchased the recalled product who have a wheat allergy are asked to return it to the original place of purchase and not to consume it, the FDA says. People with additional questions may contact the company via phone at +32 2 568 23 00 from 8 a.m. to 5 p.m. Central European Summer Time on weekdays or via email at customercare@
Newsweek
15 hours ago
- Newsweek
New Vaccine Shows Promise Against One of the Deadliest Cancers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Early clinical and preclinical results are showing that experimental mRNA and nanoparticle vaccines produced measurable immune responses against pancreatic cancer, one of the deadliest cancers, and that in small patient groups those immune responses correlated with delayed recurrence or prolonged survival. Why It Matters Pancreatic cancer has among the lowest survival rates of common cancers and limited effective treatments. Multiple small trials and preclinical studies published and reported in the past year indicated that novel vaccine platforms, including personalized mRNA vaccines and layered lipid nanoparticles, were able to induce tumor‑targeting T cells in patients and animal models, prompting researchers to plan larger trials. Pancreatic ductal adenocarcinoma had an approximate five‑year survival near 13 percent in recent reports, making it one of the most lethal common cancers. What To Know Researchers at Memorial Sloan Kettering (MSK) and collaborators ran a phase 1 trial in February testing a personalized mRNA vaccine called autogene cevumeran (BNT122, RO7198457) in 16 patients with operable pancreatic cancer who received surgery, chemotherapy and the vaccine, according to the peer reviewed journal Nature Medicine. Newsweek reached out to MSK via email for comment. The vaccine was developed and researched through a collaboration between BioNTech, an immunotherapy company, and Genentech, a member of the Roche Group. It is not a cure for the type of cancer itself; however, signs point to improving longevity in individuals who contract the disease. Investigators reported that half of participants mounted vaccine‑induced tumor‑specific T‑cell responses. Also, long-term efficacy was reported as patients with a vaccine-induced immune response had a reduced risk of cancer returning at three-year follow-up appointments compared with patients whose immune systems did not respond. Trials have occurred as cancer is on the rise this year compared to last, according to the American Cancer Society's 2025 annual Facts & Figures report. More than 2 million new cancer cases are expected this year, according to a 48-page report. Roughly 618,000 Americans are expected to die from cancer in 2025, equating to about 1,700 deaths per day, and both one-in-three men and women are said to develop cancer in their lifetime. These five cancers are predicted to take nearly 323,900 male lives in a year: Lung and bronchus—64,190 male deaths Prostate—35,770 male deaths Colon and rectum—28,900 male deaths Pancreas—27,050 male deaths Liver and intrahepatic bile duct—19,250 male deaths These five cancers are estimated to take nearly 294,220 female lives in a year, described by researchers as a "substantial" increase compared to 2024 numbers: Lung and bronchus—60,540 female deaths Breast—42,170 female deaths Pancreas—24,930 female deaths Colon and rectum—24,000 female deaths Uterine—13,860 female deaths Researchers reported early clinical and preclinical results showing that experimental mRNA and nanoparticle vaccines produced measurable immune responses against pancreatic cancer. Researchers reported early clinical and preclinical results showing that experimental mRNA and nanoparticle vaccines produced measurable immune responses against pancreatic cancer. Getty Images What People Are Saying Vinod Balachandran, a surgical oncologist at MSK and principal investigator of the February 2025 trial, said at the time of the trial's conclusion: "The latest data from the phase 1 trial are encouraging. They suggest this investigational therapeutic mRNA vaccine can mobilize anti-tumor T cells that may recognize pancreatic cancers as foreign, potentially years after vaccination." He added: "For patients with pancreatic cancer, our latest results continue to support the approach of using personalized mRNA vaccines to target neoantigens in each patient's tumor. If you can do this in pancreas cancer, theoretically you may be able to develop therapeutic vaccines for other cancer types." Immunologist Li Lily Wang, an associate professor of molecular medicine at the Case Western Reserve School of Medicine, said earlier this year: "This platform has the potential to transform clinical care for this devastating disease. I am excited to see that our novel nano-vaccine worked so well in eliciting vigorous responses from tumor-reactive T cells-which are typically low in numbers and unable to control tumor growth." What Happens Next? Researchers planned larger trials to test whether the vaccine‑induced immune responses translated into longer survival and lower recurrence rates. MSKCC and industry partners launched a phase 2 trial to evaluate the personalized pancreatic mRNA vaccine in a larger cohort following the encouraging phase 1 immune data. Across studies, authors and outside experts urged caution because the human data remained small. Investigators and commentators said larger randomized trials were necessary to determine whether the immune responses would translate into durable survival benefits and acceptable safety in broader patient populations.
